Skip to content
10-Q

Quarterly Report

NIKA PHARMACEUTICALS, INC NIKA

0001826466-25-000087

← back to feed
Filed
Aug 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 7, 2025 1.03B sh
Shares Diluted Q2 2025 · Jun 30, 2025 1.03B sh
Shares Diluted Q2 2025 · Jun 30, 2025 1.03B sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$31.47K
Short Term Debt Q2 2025 · Jun 30, 2025 $284.16K
Short Term Debt Q2 2025 · Dec 31, 2024 $239.16K
Cash And Equivalents Q2 2025 · Jun 30, 2025 $15.62K
Cash And Equivalents Q2 2025 · Dec 31, 2024 $2.08K
Stockholders Equity Q2 2025 · Jun 30, 2025 −$252.56K
Stockholders Equity Q2 2025 · Mar 31, 2025 −$234.18K
Stockholders Equity Q2 2025 · Dec 31, 2024 −$221.23K
Current Liabilities Q2 2025 · Jun 30, 2025 $284.16K
Current Liabilities Q2 2025 · Dec 31, 2024 $239.16K
Total Liabilities Q2 2025 · Jun 30, 2025 $284.16K
Total Liabilities Q2 2025 · Dec 31, 2024 $239.16K
Current Assets Q2 2025 · Jun 30, 2025 $31.61K
Current Assets Q2 2025 · Dec 31, 2024 $17.93K
Total Assets Q2 2025 · Jun 30, 2025 $31.61K
Total Assets Q2 2025 · Dec 31, 2024 $17.93K
Eps Diluted Q2 2025 · Jun 30, 2025 $0.00
Eps Diluted Q2 2025 · Jun 30, 2025 $0.00
Eps Basic Q2 2025 · Jun 30, 2025 $0.00
Eps Basic Q2 2025 · Jun 30, 2025 $0.00
Sga Expense Q2 2025 · Jun 30, 2025 $14.3K
Sga Expense Q2 2025 · Jun 30, 2025 $16.1K
Net Income Q2 2025 · Jun 30, 2025 −$18.38K
Net Income Q2 2025 · Jun 30, 2025 −$31.33K
Operating Income Q2 2025 · Jun 30, 2025 −$18.38K
Operating Income Q2 2025 · Jun 30, 2025 −$31.33K